NCT05077800 2026-04-13
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT05607017 2026-04-06
Losartan in Prevention of Radiation-Induced Heart Failure
Massachusetts General Hospital
Phase EARLY_PHASE1 Completed
NCT06211335 2026-03-12
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
University of California, Davis
Phase 1 Recruiting
NCT03900793 2026-02-03
Losartan + Sunitinib in Treatment of Osteosarcoma
University of Colorado, Denver
Phase 1 Recruiting
NCT04539808 2026-01-14
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT07265739 2025-12-11
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
Massachusetts General Hospital
Phase 2 Not yet recruiting
NCT01199978 2025-10-01
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03563248 2025-10-01
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT07160361 2025-09-16
Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB
Second Affiliated Hospital of Xi'an Jiaotong University
Phase 4 Not yet recruiting
NCT06135493 2025-04-24
Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
Future University in Egypt
Phase 2 Completed